TransCode Therapeutics

Also Clin0 glioblastoma, pancreatic cancer, RD SCLC, osteosarcoma; TTX-siPDL1 Clin0 pancreatic ductal adenocarcinoma; Cu-TTX-MC138 Clin0 breast cancer; TTX-siLin28b Clin0 pancreatic cancer; 3 additional programs RD/Clin0 oncology

TransCode Therapeutics is developing RNA-based treatments for patients with metastatic diseases. Small non-coding strands of RNA (microRNAs) have been identified as a major player in the pathology of cancer and metastasis. TransCode is investigating the microRNA, miRNA-10b, which is observed as a master regulator of viability of metastatic tumor cells. The miRNA is expressed in several cancers including breast, pancreatic, ovarian, colon and glioblastomas. By targeting this miRNA with their lead therapeutic candidate, TTX-MC138, and efficient delivery TransCode is rapidly advancing new scientific discoveries to revolutionize the way cancer is treated to significantly improve patient outcomes.

Jobs: